ATAI Life Sciences BV (NASDAQ: ATAI) — Cash Is Settled; Milestones Carry the Risk

Published: 2026-09-11 · Verdict: Sell · Research confidence: High (94%)

Executive conclusion

Analyst Take

Eli Lilly completed its acquisition of AtaiBeckley on September 11, 2026. That event ends the ordinary public-equity thesis: ATAI common shares no longer represent ownership in a standalone biotechnology company and are not available for a new position. Each eligible share was converted into $6.75 of cash plus one nontransferable contingent value right, or CVR, that can pay up to a nominal $2.50 if three specified development and regulatory milestones occur before contractual deadlines. The appropriate administrative designation is SELL, with no entry price and no conventional price target, because there is no continuing listed security to buy or value. Former shareholders instead hold a bounded, illiquid contractual claim against Lilly whose economics must be separated from the headline maximum consideration. [S1][S2][S3]

The last regular-session close on September 10 was $7.35. Subtracting the fixed $6.75 cash leg produces a pre-closing market-implied CVR value of approximately $0.60. That was 76% below the $2.50 nominal maximum and below the $0.85-$0.90 range calculated by Moelis using management-supplied probabilities and timing assumptions and discount rates of 13.25%-15.75%. Centerview separately calculated approximately $0.87 at a 15% discount rate. Neither adviser estimate was an independent clinical forecast: both were fairness-analysis inputs informed by management. Nor was the $0.60 spread a riskless mispricing. The right cannot ordinarily be transferred, will not be listed, pays no interest, is a general unsecured obligation after any payment becomes due, can be reduced by specified intellectual-property offsets, and can expire at zero. [S3][S22]

The scientific case has real merit. BPL-003 is intranasal mebufotenin for treatment-resistant depression, or TRD. In a 193-patient randomized Phase 2b trial, Day 29 MADRS scores declined by 12.0 points with 8 mg and 11.2 points with 12 mg, versus 5.8 points with a 0.3 mg comparator; both comparisons were reported at p<0.01. Improvement appeared early and was observed through Week 8, while average discharge readiness was within approximately two hours. The company selected 8 mg for pivotal development because efficacy was comparable to 12 mg with lower treatment-emergent adverse-event burden. FDA Breakthrough Therapy designation and regulator-aligned pivotal planning add credibility. These are meaningful facts, but they are not proof of approval, durable commercial benefit, or superior clinic economics. [S7][S10]

The strongest bull case is that Lilly acquired a scarce, clinic-compatible neuropsychiatry franchise at the point when better evidence, commercial validation from Spravato, positive late-stage peer results, and clearer FDA guidance were making the category institutionally investable. Lilly can finance Phase 3 trials, manufacturing, regulatory work, and commercialization without issuing ATAI shares. The strongest counter-case is that $2.00 of the CVR’s $2.50 maximum depends on VLS-01, which had completed dosing but had not reported randomized patient efficacy by the cutoff. BPL-003 must also replicate despite functional-unblinding risk, demonstrate acceptable repeated-dose safety, obtain FDA approval, and complete DEA rescheduling before the fifth anniversary. Lilly’s commercially reasonable efforts standard permits consideration of portfolio priorities, competitors, safety, market conditions, intellectual property, supply, and prudent business judgment; it is not a promise to maximize CVR value at any cost. [S3][S8][S10]

ATAI’s historical financial record tempers the asset-validation narrative. The company generated no approved-product revenue, reported cumulative operating losses of roughly $678 million from 2021 through the first half of 2026 before the separately presented acquired-IPR&D charge, and used approximately $437 million of operating cash during 2021-2025. The Beckley transaction committed approximately $519.6 million of economic value, while its accounting produced a $527 million acquired-IPR&D charge. Reported R&D over 2021 through the first half of 2026 totaled approximately $338.5 million, but adding all of those figures into a single return denominator would risk double counting embedded research. The defensible conclusion is qualitative but firm: no positive realized ROIC was demonstrated, and a precise research-adjusted ROIC cannot be calculated from public asset-level data. [S4][S5]

Conviction is high that the listed-equity thesis has ended and moderate on CVR value. Transaction completion, consideration, voting, deadlines, offsets, and transfer restrictions are documented in primary filings. Historical financial data reconcile to SEC filings. BPL-003 has randomized evidence but remains sponsor-reported and unreplicated in Phase 3. VLS-01 lacked patient-efficacy results as of the cutoff. The decision sequence is now VLS-01 Phase 2 topline data, qualifying VLS-01 Phase 3 first-patient dosing by September 11, 2030, BPL-003 pivotal results expected around early 2029, FDA decisions, DEA rescheduling, and rights-agent payment notices. The administrative call would change only if a tradable successor security emerged or the transaction were legally unwound. CVR value would change materially upon a failed VLS-01 readout, a BPL-003 pivotal miss, a serious repeat-dose safety signal, missed regulatory deadlines, disclosure of large offsets, or formal achievement of a milestone.

Stock Price Action — Five-Year Event Map

ATAI’s five-year history illustrates the capital cycle of pre-commercial biotechnology: abundant early funding, pipeline proliferation, clinical attrition, retrenchment, concentration around a better asset, and strategic sale. The recorded closing high was $19.89 on June 21, 2021; the recorded five-year closing low was approximately $1.04 on November 30, 2023; and the final September 10, 2026 close was $7.35, within roughly 1.3% of the reported 52-week intraday high of $7.45. Price facts below are separated from attributed drivers, which remain interpretations. [S21][S22]

• June 2021—IPO and peak. Reported fact: ATAI priced 15 million shares at $15 for $225 million of gross proceeds; the underwriters’ option later brought the total issuance to 17.25 million shares. The first-session intraday high was $22.91, and the June 21 closing high was $19.89. Interpretation: investors initially assigned considerable option value to a diversified psychedelic-development platform and a large cash balance, before clinical attrition or tighter financing markets tested the diversification thesis. [S21][S22]

• 2022—platform de-rating. Reported fact: operating loss increased to $144.4 million from $120.3 million, while revenue fell from $20.4 million to $0.2 million. Management’s third-quarter commentary emphasized eight clinical programs, four enabling technologies, and an intended at-home profile for PCN-101. Interpretation: higher discount rates, a weaker small-biotechnology financing market, and growing recognition that platform breadth did not create recurring economics reduced the value assigned to distant options. [S5][S22]

• January 2023—PCN-101 disappointment. Reported fact: a 102-patient randomized Phase 2a study missed its 24-hour primary endpoint. The 60 mg arm improved MADRS by 15.3 points versus 13.7 for placebo, a placebo-adjusted difference of only 1.6 points with p=0.5. The stock fell from $2.63 on January 5 to $1.82 on January 6, a 30.8% regular-session close-to-close decline. Interpretation: the result impaired both the asset and management’s earlier narrative that R-ketamine could provide robust antidepressant benefit with a differentiated at-home profile. [S18][S22]

• November-December 2023—cycle low. Reported fact: the stock closed at approximately $1.04 on November 30, and cash plus marketable securities had declined materially from the post-IPO period. Interpretation: investors were increasingly treating ATAI as a financing-dependent collection of early clinical options rather than a de-risked platform. The subsequent retrenchment was therefore as much a response to the capital market as to portfolio evidence. [S22][S25]

• 2024—narrowing without durable re-rating. Reported fact: revenue remained approximately $0.3 million, operating loss was $102.2 million, and year-end cash and short-term securities were approximately $62.3 million. Interpretation: reduced spending lengthened runway but did not solve the absence of a pivotal asset, recurring revenue, or internally funded development. [S5][S24]

• 2025—Beckley consolidation and BPL-003 validation. Reported fact: ATAI completed the Beckley acquisition on November 5. Total merger consideration included 103.8 million common-share equivalents for sellers, not merely the approximately 81.3 million shares covered by one later registration statement. The accounting fair value of consideration paid was $465.6 million, and the carrying value of ATAI’s pre-existing interest was $53.9 million. BPL-003 produced positive randomized Phase 2b results, while year-end common shares outstanding rose to 363.3 million from 168.0 million. Interpretation: enterprise value migrated from the original broad platform toward a later-stage, short-duration TRD asset, but per-share value still depended on very large issuance and future financing. [S4][S5][S7]

• First half of 2026—pivotal planning and strategic alternatives. Reported fact: BPL-003 entered FDA-aligned Phase 3 planning, VLS-01 completed enrollment and later dosed its last patient, and EMP-01 reported exploratory results. The merger proxy records partnership discussions and a strategic-alternatives process. Interpretation: stronger evidence increased negotiating leverage, while the scale and timing of future funding made partnership or sale economically important rather than merely optional. [S3][S7][S8][S9]

• July-September 2026—takeover convergence. Reported fact: Lilly agreed to pay $6.75 cash plus a CVR of up to $2.50, describing the fixed cash as a 40% premium to the prior 30-day VWAP. The September 10 close was $7.35, and Lilly completed the acquisition the next day. Interpretation: after announcement, most price variation represented changes in closing probability and the market-implied value of the CVR, including liquidity, tax, offset, and timing discounts—not changes in the value of an independently financed ATAI. [S1][S3][S6][S22]

The final consideration does not erase the long-run loss for early holders. The $6.75 cash leg was below the $15 IPO price. Even receipt of the full $2.50 nominal CVR would produce $9.25 before time value, still below the IPO and far below the initial peak. Conversely, buyers near the 2023 trough earned a substantial outcome. Entry price, dilution, and time therefore mattered as much as whether one asset ultimately attracted a strategic acquirer.

Verdict: The price record supports neither a simple success story nor an unqualified failure story. BPL-003 and the Beckley transaction created enough strategic value to attract Lilly, but the original platform consumed capital, suffered attrition, and delivered a bounded exit below the IPO price. [S1][S5][S18]

Business Overview

AtaiBeckley was a clinical-stage biotechnology company developing rapid-acting neuropsychiatric therapies. It had no approved product. Its model was to acquire, license, incubate, or consolidate intellectual property; finance preclinical and clinical evidence; perform manufacturing and regulatory work; and monetize successful candidates through partnership, asset sale, or eventual commercialization. After the November 2025 Beckley combination, value became concentrated in BPL-003, VLS-01, and, to a lesser extent, EMP-01 and discovery programs. [S4][S5]

The economic model was readily understandable but not readily forecastable: cash was converted into clinical evidence and intellectual property, while value depended on binary efficacy, safety, regulatory, financing, and timing probabilities. Trial execution, manufacturing development, regulatory engagement, portfolio prioritization, and licensing are comprehensible operating activities. Forecasting asset value is harder because one study can eliminate years of expected cash flow, and a successful clinical result can still fail to create commercial returns if the label, monitoring burden, intellectual property, reimbursement, or retreatment economics are unattractive.

Programs and customer value

BPL-003 is a proprietary intranasal formulation of mebufotenin benzoate, a synthetic form of 5-MeO-DMT, being developed for TRD. The proposed patient value is rapid antidepressant benefit after infrequent supervised administration. The proposed provider value is a shorter episode than longer-acting psychedelic treatments. The Phase 2b program reported average discharge readiness within approximately two hours, and the planned pivotal trials did not require adjunctive psychotherapy. If that profile survives approval, a clinic could potentially treat more patients per room and staff-hour than with six- to eight-hour sessions. [S7][S10]

That proposition must be translated into total episode economics. A clinic still needs screening, drug preparation, two session monitors under current FDA guidance, vital-sign management, post-session assessment, transportation procedures, and documentation. A payer evaluates the medicine’s net price plus personnel, facility use, retreatment frequency, and avoided downstream care. A two-hour pharmacological experience is therefore not automatically a two-hour reimbursable episode, and room throughput is not automatically contribution profit.

The BPL-003 Phase 2b trial randomized 193 participants among 0.3 mg, 8 mg, and 12 mg. Day 29 MADRS change was -5.8, -12.0, and -11.2 points, respectively. The company reported both active-dose comparisons at p<0.01 but did not provide exact p-values in the cited presentation. Treatment-emergent adverse events occurred in 73% of the low-dose group, 76% at 8 mg, and 85% at 12 mg; drug-related events occurred in 34%, 70%, and 82%. In the extension, one participant experienced drug-related dissociation and suicidal ideation after a second 12 mg dose, required inpatient monitoring, and recovered the following day. That isolated resolved event does not invalidate the program, but it makes repeated-dose safety a pivotal issue. [S7]

VLS-01 is a buccal film formulation of DMT intended to produce a controlled psychedelic exposure compatible with an approximately two-hour interventional-psychiatry workflow. Elumina randomized 156 TRD patients 1:1 to VLS-01 or placebo, with two doses administered two weeks apart and a Day 29 MADRS primary endpoint. The last patient was dosed on July 6, 2026; topline data were expected in the fourth quarter. The release was an enrollment and dosing update, not an efficacy result. [S8]

VLS-01 is disproportionately important to former shareholders. Starting a qualifying Phase 3 trial before the fourth anniversary can pay up to $1.00, and approval plus DEA rescheduling before the seventh anniversary can pay another $1.00. Thus 80% of the CVR’s nominal maximum depends on a program that lacked randomized patient-efficacy results at closing. Management discussed broader MDD and GAD plans if data and regulatory feedback were supportive, but the CVR’s commercially reasonable efforts provision does not generally require simultaneous pursuit of those broader indications. [S3][S8]

EMP-01 is oral R-MDMA for social anxiety disorder. In an exploratory Phase 2a study, 71 participants were enrolled, 70 dosed, and 69 completed the Day 43 assessment. Two 225 mg administrations produced an 11.85-point placebo-adjusted improvement on the Liebowitz Social Anxiety Scale, Hedges’ g of 0.45, and a one-tailed p-value of 0.036; CGI-I response was 49% versus 15% for placebo. Safety and tolerability—not registrational efficacy—were the primary objective. Management’s comparisons with chronic SSRI or SNRI therapy were cross-trial observations, not randomized head-to-head evidence. EMP-01 is excluded from the CVR, so its residual upside belongs to Lilly. [S9]

Revenue, customers, and segment economics

Revenue was not stable in an investable sense: AtaiBeckley had no approved product, and reported annual revenue of $20.4 million in 2021, $0.2 million in 2022, $0.3 million in 2023, $0.3 million in 2024, and $4.1 million in 2025 consisted of license, research-service, or collaboration income rather than recurring therapeutic sales. First-half 2026 revenue was $2.7 million. The 2021 amount should not be used as a base for a compound growth calculation, and 2025’s increase did not represent commercial launch. [S4][S5]

ATAI did not report commercial segments with observable gross margins. Its controlled subsidiaries, investments, and product candidates were development vehicles and real options rather than operating divisions with stable customers. Program-level valuation therefore needs an explicit funnel: eligible patients, verified treatment failures, referral, contraindication screening, payer authorization, patient willingness, site capacity, net price, retreatment interval, manufacturing costs, clinic economics, royalties, and postmarketing obligations. Applying an enterprise revenue multiple to incidental licensing income would produce no decision-useful result.

Before the sale, the practical providers of cash were equity investors, lenders, partners, and prospective acquirers. The potential medical customers—treatment centers, psychiatrists, payers, and patients—would become economic customers only after approval. This distinction explains why reported revenue offered little information about the company’s ability to fund itself.

Unrecognized assets and accounting scope

The principal unrecognized assets were human capital, clinical data, regulatory designations, trial infrastructure, formulation know-how, patents, and options on product candidates, because most internally generated research was expensed rather than recorded at fair value. A favorable trial or Breakthrough Therapy designation did not create a conventional balance-sheet intangible. Conversely, unsuccessful research consumed cash without creating an asset that later appeared as an impairment.

The Beckley transaction illustrates the mismatch. The company concluded that the acquired research had no alternative future use and immediately recorded approximately $527 million of acquired IPR&D expense. The economic consideration consisted of approximately $465.6 million of fair-value consideration paid plus a $53.9 million carrying value for ATAI’s pre-existing interest. The accounting charge was not a current-period cash payment and should be excluded from normalized operating comparisons, but the acquired research was not costless. Its actual consideration and subsequent development spending belong in any research-adjusted return framework. [S4][S5]

Public patent disclosure described strategies involving drug substance, salts, polymorphs, formulations, delivery systems, and methods of use, but it did not supply a claim-level schedule sufficient to determine practical exclusivity for BPL-003 or VLS-01. Both use known psychoactive molecules, increasing the importance of formulation, delivery, regulatory exclusivity, manufacturing know-how, and enforceability. Lilly’s diligence is a positive signal; it is not a substitute for independent claim analysis.

Security and tax form

ATAI was ordinary common stock of a Delaware corporation immediately before closing, not an ADR, MLP, partnership, or K-1 issuer. At completion, the common shares converted into cash plus a nontransferable CVR. The merger proxy describes uncertain U.S. tax treatment, including possible open- and closed-transaction approaches, but also states that Lilly intended not to report the transaction under the open-transaction method. Basis allocation, imputed interest, loss timing, account type, residence, and withholding can change individual outcomes; holders need tax advice rather than a universal rule. [S3][S4]

Following completion, AtaiBeckley became a wholly owned Lilly subsidiary. Former shareholders therefore have no residual ownership of EMP-01, discovery programs, acquired cash, staff, patents, manufacturing savings, future sales, or Lilly’s broader neuroscience portfolio. Their only continuing economic exposure is the CVR contract.

Verdict: The pre-close business was understandable as a portfolio of clinical options but lacked recurring product revenue, segment economics, or self-funding capacity. Its principal assets were clinically meaningful yet contingent, and the sale narrowed former-holder exposure from an operating company to three contractual milestones. [S1][S3][S5]

Industry Dynamics

The economically relevant industry is regulated, rapid-acting, intermittently administered neuropsychiatric treatment delivered under clinical supervision—not the entire mental-health market and not psychedelics as a cultural category. The profit pool combines pharmaceutical intellectual property with a service-delivery system. A molecule can demonstrate antidepressant activity yet fail commercially if administration consumes scarce rooms and staff, monitoring remains long, payers resist total episode cost, or repeated treatment is required more frequently than expected.

Demand and addressable geography

NIMH estimates that 21.0 million U.S. adults, or 8.3% of the adult population, experienced a major depressive episode in 2021; 14.5 million experienced severe impairment. Those data establish scale but not BPL-003’s addressable market. NIMH also cautions that methodology changes limit historical comparability. TRD definitions vary, and an independent systematic review used failure of at least two adequate treatments as its threshold. [S16][S17]

Demand is primarily U.S.-led for CVR valuation because the two approval milestones require U.S. FDA approval and DEA rescheduling, although development and eventual treatment demand can be international. A realistic addressable-market funnel begins with diagnosed MDD, verified failure of prior therapy, referral to interventional psychiatry, contraindication screening, insurance authorization, patient willingness to undergo an altered state, access to transportation and support, treatment-center capacity, and repeat-treatment adherence. Multiplying all people with depression by a hypothetical drug price would grossly overstate revenue.

The independent network meta-analysis covered 69 randomized trials, 10,285 participants, and 25 treatments through April 2023. Only six individual treatments—ECT, minocycline, theta-burst stimulation, repetitive TMS, ketamine, and aripiprazole—showed statistically significant response advantages versus placebo in that synthesis. Serotonergic psychedelics did not emerge as a significant treatment group in the available dataset. Evidence quality and trial heterogeneity were important limitations. This is material disconfirming evidence: unmet need and enthusiastic sponsor readouts do not mean the category has already established comparative effectiveness. [S17]

International demand may ultimately be meaningful, but scheduling, psychotherapy practice, controlled-substance law, reimbursement, and clinical infrastructure differ materially by jurisdiction. International trial sites can accelerate recruitment and reduce expense; they do not remove the need for acceptable U.S. evidence or local treatment delivery.

Existing proof of a profit pool

Spravato supplies the strongest proof that a supervised rapid-acting depression product can scale commercially. Worldwide sales increased from $689 million in 2023 to $1.077 billion in 2024 and $1.696 billion in 2025; 2025 U.S. sales were $1.485 billion. That validates patient, provider, and payer willingness to use a supervised medicine. It does not establish BPL-003’s price, penetration, margin, or durability. [S12]

Spravato also reveals the service burden. Its label provides twice-weekly induction during Weeks 1-4, weekly administration during Weeks 5-8, and weekly or every-two-week maintenance thereafter. Treatment occurs under direct supervision in a certified setting, with monitoring for at least two hours and driving prohibited until the next day after restful sleep. A future product administered four to six times annually could reduce visits materially if response and durability hold, but the comparison must include differences in evidence, label, severity, patient selection, and retreatment. [S11]

FDA’s final psychedelic guidance sets a meaningful operational floor. The agency expects two monitors during the treatment session, including a qualified lead monitor; prompt physician access may also be necessary. The guidance calls for controls against functional unblinding, durability assessment, repeat-dose safety, abuse-potential evidence, and characterization of psychotherapy’s contribution. A short psychoactive duration can improve capacity, but it cannot eliminate staffing, observation, or controlled-substance compliance. [S10]

Named competitors

Compass Pathways and COMP360. Compass reported positive primary endpoints in two Phase 3 psilocybin studies, had begun a rolling NDA submission, and expected completion in the fourth quarter of 2026. It was preparing for a possible first-half 2027 launch, subject to approval and rescheduling. At June 30 it reported $433.3 million of cash and equivalents and $50.7 million of debt, with runway expected into 2028. COMP360 was therefore materially ahead of BPL-003 in regulatory timing, although its treatment sessions are longer. Compass’s assertions about thousands of potentially capable centers and blockbuster potential remain sponsor estimates. [S13]

GH Research and GH001. GH001 is inhaled mebufotenin and is the closest mechanism-and-duration competitor. After FDA lifted its clinical hold in January 2026, GH targeted a global Phase 3 start during 2026. The sponsor reported a 15.5-point placebo-adjusted Day 8 MADRS improvement, 57.5% remission, an approximately 11-minute median psychoactive experience, and 99% discharge readiness within one hour. These data directly challenge any assertion that BPL-003 uniquely controls short-duration mebufotenin. They do not establish superiority because control, eligibility, baseline severity, dosing, endpoints, and study conduct differ across trials. [S14]

Definium and DT120. Definium reported that a single 100 microgram dose of its lysergide orally disintegrating tablet produced an 8.1-point placebo-adjusted Week 6 MADRS improvement in a 149-patient Phase 3 MDD trial, with p<0.0001, and a 7.3-point difference at Week 12. Average discharge readiness was 5.8 hours, and all patients were ready by eight hours. This is much less clinic-efficient than BPL-003’s target, but Definium had positive pivotal evidence in a broader depression population. The disclosure was sponsor-reported and awaits full independent evaluation. [S15]

Spravato and established modalities. Spravato has commercial incumbency, prescriber familiarity, an existing REMS network, and payer experience. ECT, TMS, ketamine clinics, oral augmentation, psychotherapy, and conventional antidepressants remain relevant substitutes. Competition is therefore between modalities and care pathways, not merely between molecules sharing a receptor.

Competition is becoming more intense: positive late-stage results, large financings, an approved incumbent, and strategic acquisitions are bringing more credible capital into the same interventional-psychiatry channel. That helps build sites, payer familiarity, and physician awareness, but it also raises the evidence bar and reduces the scarcity value of any single formulation. [S6][S12][S13][S14][S15]

Capital cycle and industry profitability

The supply-side capital cycle moved from exuberant public financing in 2020-2021 to broad retrenchment during 2022-2024 and renewed strategic investment after stronger clinical results. ATAI’s IPO financed many programs; failures and a weak market forced narrowing; BPL-003 then attracted a large pharmaceutical buyer. Capital availability is now improving selectively for later-stage, differentiated assets, while early programs without convincing evidence still face high financing costs.

Industry profitability is bifurcated: an approved differentiated product such as Spravato can generate billion-dollar revenue, while pre-commercial peers continue to report substantial R&D and administrative losses. Compass, for example, reported first-half 2026 R&D expense of $55.7 million and G&A of $39.6 million despite having no approved product. The category’s eventual molecule-level gross margins may be attractive, but total economics must support the drug developer, treatment center, monitoring professionals, distributor, and payer. [S12][S13]

Barriers to entry are meaningful but do not guarantee a moat:

1. Clinical replication. Sponsors need persuasive randomized evidence across endpoints and trials. Functional unblinding can amplify expectancy, while placebo response in depression is often high. Central raters and expectancy questionnaires reduce but do not eliminate bias. [S10]

2. Repeat-dose safety and durability. A chronic disease requires evidence beyond an early endpoint. FDA expects a meaningful controlled follow-up and typically longer safety observation. Suicidality, dissociation, blood pressure, abuse potential, and cumulative exposure can affect the label. [S7][S10]

3. CMC and delivery. Intranasal and buccal systems create formulation and device risks. Exposure consistency, purity, scale-up, packaging, stability, and controlled-substance handling must meet commercial standards.

4. Regulation and scheduling. Schedule I research requires DEA compliance. Approval supplies the basis for movement into Schedule II-V, but scheduling remains a separate legal process and therefore a distinct CVR timing condition. [S3][S10]

5. Clinic integration. Sites require trained personnel, monitoring rooms, emergency procedures, transport policies, documentation, and reimbursement workflows. Existing Spravato or ketamine infrastructure helps the industry but is not proprietary to ATAI.

6. Intellectual property. Known molecules shift value toward formulations, delivery systems, dosing regimens, methods of use, regulatory exclusivity, manufacturing know-how, and enforceability. A patent count alone does not establish durable exclusion.

7. Capital and time. Multiple adequate pivotal trials, long-term safety databases, validated manufacturing, regulatory submissions, and launch infrastructure require hundreds of millions of dollars over years.

Foreign low-cost labor or manufacturing was not the primary competitive threat because regulated clinical evidence, CMC, controlled-substance handling, intellectual property, and local treatment delivery dominate economics. International trials or lower-cost manufacturing can improve a rival’s cost structure, but cannot substitute for acceptable evidence or U.S. treatment infrastructure. [S4][S10]

Regulation as barrier and cost

The July 2026 FDA guidance reduced policy ambiguity while making the development burden explicit. For chronic illnesses such as depression, the agency expects assessment of durability, repeat dosing, functional unblinding, prior psychedelic exposure, concomitant therapy, psychotherapy’s contribution, and longer-term safety. The guidance favors well-capitalized sponsors with standardized protocols. It also risks narrowing the apparent throughput advantage if the approved label requires observation materially beyond the pharmacological experience. [S10]

Verdict: The market has large unmet need and demonstrated commercial demand, but it is neither empty nor winner-take-all. Capital, competitors, and regulatory clarity are increasing together. BPL-003’s short-session profile could matter, but durable industry profit requires replicated outcomes, reimbursement, clinic contribution, and defensible protection—not psychedelic novelty. [S10][S12][S17]

Competitive Position

ATAI’s strongest competitive position was concentrated in BPL-003. The original platform strategy did not create observable recurring economics or reliable diversification: PCN-101 failed its proof-of-concept endpoint, programs were narrowed, and ATAI ultimately consolidated Beckley to acquire a more advanced lead asset. Competitive analysis should therefore focus on BPL-003’s clinical and workflow profile, VLS-01’s formulation option, and Lilly’s post-close ability to fund execution. [S4][S18]

BPL-003’s potential edge

The Phase 2b trial supports three differentiated claims. First, both selected active doses produced approximately five- to six-point greater Day 29 MADRS improvement than the 0.3 mg comparator. Second, improvement was observed early and persisted through the controlled Week 8 observation. Third, average discharge readiness was within approximately two hours. Those facts support further development and the possibility of a clinic-capacity advantage. [S7]

The economic moat would not be the compound’s novelty. Mebufotenin is known, and GH001 uses the same active molecule through a different route. The prospective moat is an integrated profile: reproducible efficacy, tolerability at 8 mg, short administration, convenient intranasal delivery, feasible retreatment, a workable label, manufacturing consistency, and intellectual-property or regulatory protection. Each component must produce an operating outcome. Without the duration advantage, room utilization falls. Without adequate durability, visit frequency rises. Without reimbursement, eligible patients do not become paid treatments. Without protection, price and terminal value compress.

The 8 mg dose was selected because efficacy was similar to 12 mg while adverse-event incidence was lower. That is sensible dose optimization, but the tolerability difference does not establish a low-risk profile. Drug-related events occurred in 70% at 8 mg, and repeated-dose data remain limited. Nausea, headache, nasal discomfort, transient blood-pressure increases, anxiety, and vomiting affect patient acceptance and staffing. The serious event after open-label redosing is particularly relevant because commercial use would probably involve retreatment. [S7]

Trial design and functional unblinding

The ReConnection program was designed to address several weaknesses common to psychedelic studies. ReConnection-1 contemplated approximately 350 patients randomized among 8 mg, 4 mg, and placebo, while ReConnection-2 contemplated approximately 300 patients receiving two 8 mg or placebo doses on Days 1 and 15. Both used Week 4 MADRS change as the primary endpoint, remote independent raters, and no adjunctive psychotherapy. Extensions contemplated individualized retreatment at eight- or twelve-week intervals. [S7]

The sponsor’s presentation contained an internal timing inconsistency: detailed design slides described a 12-week double-blind period, while a summary slide referred to eight weeks. This may reflect different definitions or presentation shorthand, but final protocols and trial registrations—not an investor slide—should control analysis. The inconsistency modestly lowers confidence in precise public descriptions of the pivotal design.

FDA explicitly identifies intense perceptual effects as a source of functional unblinding. Participants, monitors, and even remote raters may infer assignment, changing expectations and symptom reporting. A low active comparator or dose-response arm helps, but a perceptible psychedelic experience can remain obvious. Strong evidence would include successful primary endpoints in both studies, coherent response and remission measures, durability, results stratified by prior psychedelic exposure, site consistency, and disclosed guesses of treatment assignment. [S10]

Comparison with GH001, COMP360, and DT120

GH001 directly attacks BPL-003’s short-duration position. Its sponsor-reported median psychoactive experience was 11 minutes and discharge readiness within one hour for 99% of participants. If reproduced in Phase 3 with acceptable safety and monitoring requirements, GH001 could offer even better throughput. BPL-003 may counter with an intranasal delivery system, a more advanced FDA-aligned plan, or different efficacy and durability, but cross-trial evidence cannot settle the ranking. [S14]

COMP360 has the regulatory timing advantage. Two positive pivotal studies and a rolling NDA create potential first-mover benefits in trained sites, payer contracts, prescriber familiarity, and real-world evidence. Its longer sessions reduce theoretical room utilization, but superior evidence, earlier approval, or more durable response can outweigh session length. [S13]

DT120 offers positive Phase 3 evidence in MDD and a longer controlled benefit, but its 5.8-hour average discharge time makes the capacity burden visible. A clinic choosing among products will compare expected contribution per occupied room-hour, staff intensity, cancellation risk, adverse-event resources, retreatment, and payer reimbursement—not duration alone. [S15]

Brand, switching costs, and treatment-channel ownership

Brand did not yet create product economics because no ATAI medicine was approved; prescribers and payers were evaluating evidence, safety, label, access, and workflow rather than consumer brand recognition. Corporate reputation mattered for recruiting investigators, employees, partners, and capital, but it was not an end-market moat. Lilly’s brand and commercial infrastructure may improve regulator, payer, and provider execution after closing, while the product label remains foundational. [S1][S5]

Competition is multimodal and evidence-driven: BPL-003 competes with drugs, devices, procedures, psychotherapy, and other supervised psychedelics on efficacy, durability, safety, session length, retreatment frequency, reimbursement, and patient acceptance. [S11][S12][S13][S14][S15]

Switching costs were low before approval and would likely be moderate rather than prohibitive after launch because treatment centers can reuse rooms, staff, and payer processes across products, although REMS certification, training, protocols, formulary authorization, and clinician familiarity create friction. Shared interventional-psychiatry infrastructure can become an industry asset rather than a proprietary network. A site may carry several products and route patients according to label, duration, contraindications, payer rules, and response.

Patient-level switching friction may be greater once a treatment works: physicians and patients may avoid changing a successful regimen because relapse risk and another altered-state experience are undesirable. Payers can create the opposite pressure through step edits and preferred products. Neither mechanism resembles a closed technology ecosystem.

Intellectual property and exclusivity

ATAI described issued and pending patents involving drug substance, salts, polymorphs, formulations, delivery, and methods of treatment, but the filings reviewed did not provide a complete claim-level expiry and enforceability schedule for BPL-003 and VLS-01. Known molecules increase dependence on secondary patents and regulatory exclusivity. A base valuation should therefore avoid assuming that every expected patent family issues with commercially blocking claims or survives challenge.

The missing evidence is specific: issued U.S. claims, pending claims, ownership and license terms, potential Orange Book eligibility, patent-term adjustment, patent-term extension, regulatory exclusivity, freedom to operate, and realistic generic or alternative-formulation workarounds. Lilly’s acquisition validates that the package passed a strategic buyer’s diligence threshold, not that litigation risk is zero.

Lilly’s post-close advantage and contractual limits

Lilly supplies capital, clinical operations, CMC systems, regulatory expertise, payer relationships, and global commercialization capacity. This substantially reduces the probability that an otherwise promising trial is delayed solely because ATAI cannot raise equity. It may also improve manufacturing scale and launch readiness.

For CVR holders, however, Lilly’s capabilities are not equivalent to an unconditional effort covenant. The negotiated commercially reasonable efforts standard allows consideration of Lilly’s portfolio, competitor activity, safety, efficacy, proprietary position, market conditions, supply, and prudent business judgment. It does not require pursuing multiple indications simultaneously, and AtaiBeckley did not obtain every anti-frustration protection it requested. Lilly has a powerful economic reason to develop valuable products, but it can rationally terminate weak or uneconomic programs even when that eliminates a CVR payment. [S3]

Verdict: BPL-003 possessed credible randomized evidence and a plausible workflow advantage, but no proven moat. A durable advantage requires pivotal replication, feasible repeat dosing, superior clinic contribution, broad reimbursement, and enforceable protection. Lilly improves execution capacity; it does not remove molecule, trial, competitive, or contractual risk. [S3][S7][S10][S14]

Growth History and Forward Opportunities

Historical revenue growth is not the right measure for ATAI. The relevant growth was movement of product candidates through clinical and regulatory stages and the change in probability-weighted future cash flows. That history was uneven: early portfolio breadth, PCN-101 failure, retrenchment, Beckley consolidation, BPL-003 validation, and sale.

The product outlook is strongest for BPL-003, which has randomized Phase 2b evidence and an FDA-aligned pivotal program; VLS-01 is a less-de-risked Phase 2 option whose data determine most nominal CVR value, while EMP-01 is encouraging but earlier and excluded from the CVR. [S3][S7][S8][S9]

BPL-003 pathway

The ReConnection trials were expected to report around early 2029. ReConnection-1 evaluates single-dose efficacy and dose response; ReConnection-2 evaluates a two-dose induction. Long-term follow-up is meant to characterize durability, retreatment, and safety. Development value depends on several sequential events:

• clinically meaningful and statistically persuasive Week 4 MADRS separation in both pivotal studies;
• response, remission, and durability consistent with the primary endpoint;
• repeat-dose safety acceptable for a chronic condition;
• evidence robust to functional unblinding, site effects, prior psychedelic exposure, and concomitant antidepressants;
• manufacturing and device validation;
• a label and REMS that preserve practical clinic efficiency;
• FDA approval and DEA rescheduling before September 11, 2031; and
• eventual reimbursement and treatment-center adoption.

The BPL CVR payment is only $0.50. That asymmetry is important: BPL-003 could become strategically valuable to Lilly while former ATAI shareholders receive only a bounded milestone amount and no sales participation.

VLS-01 pathway

The Elumina study is the nearest unresolved fundamental catalyst. Its primary endpoint is Day 29 MADRS change after two doses two weeks apart; secondary observations extend through Weeks 6 and 14 and include safety and suicidality assessments. The first $1.00 milestone requires first dosing of the first patient in a qualifying Phase 3 trial before the fourth anniversary. A favorable press release, an FDA meeting, trial registration, or site activation is insufficient unless the contractual first-patient criterion is satisfied. [S3][S8]

A positive Phase 2 result must be translated into dose selection, regulator alignment, protocol completion, CMC readiness, site activation, and first-patient dosing. The second VLS payment requires FDA approval plus DEA rescheduling before the seventh anniversary. It therefore depends on Phase 2 success, timely pivotal initiation, registrational replication, a complete safety and manufacturing package, NDA acceptance and approval, and scheduling before September 11, 2033.

The two VLS milestones are correlated. A strong Phase 2 result raises both probabilities; a fundamental safety or efficacy failure can impair both simultaneously. They should not be valued as independent coin flips.

EMP-01 and discovery options

EMP-01’s medium standardized effect and CGI-I response justify further study, especially in a social-anxiety market with limited recent innovation. The result remains exploratory: safety was the primary objective, efficacy used a one-tailed test, the trial was modest in size, and there was no active comparator. Several-hour psychoactive effects may also produce less favorable throughput than BPL-003. Further randomized dose-ranging and longer follow-up would be necessary before assigning high approval probability. [S9]

Non-hallucinogenic neuroplasticity discovery could eventually produce conventional outpatient medicines without supervised altered-state sessions. Those programs were too early for a decision-useful valuation and are excluded from the CVR. Their upside transferred entirely to Lilly.

Management forecasts and financing dependence

The merger-case forecasts projected no material product revenue through 2029, then $13 million in 2030, $88 million in 2031, $263 million in 2032, $544 million in 2033, and $890 million in 2034. Later years exceeded $4 billion. Those figures were unaudited transaction forecasts, not guidance or reported fact, and depended on approvals, market penetration, pricing, retreatment, exclusivity, and commercialization spending. [S3]

The same forecast package assumed negative free cash flow through 2031 and approximately $1.25 billion of external capital: around $300 million of royalty-linked financing and $950 million of equity raises during 2026, 2027, 2028, and 2030. This contradicts any interpretation that the June 2026 balance sheet fully funded the independent commercial opportunity. A previously communicated runway through early 2029 referred to a defined operating plan, not the complete path to launch. [S3][S7]

Lilly changes the financing path. The programs can now be funded from a large pharmaceutical balance sheet, eliminating ATAI share issuance. Former shareholders exchanged open-ended upside and dilution risk for fixed cash and limited milestone exposure.

Verdict: The assets retain substantial clinical opportunity, but growth remained long-dated, binary, and economically capital-intensive. Lilly is better positioned to fund the path; former ATAI investors participate only in three milestones rather than commercial revenue or terminal value. [S1][S3][S8]

Financial Quality

AtaiBeckley was not an earnings business. It was a research-financing vehicle whose outputs were evidence, intellectual property, and strategic options. P/E, EBITDA, gross-margin, and ordinary accounting-ROIC comparisons are therefore either negative or misleading.

Multi-year operating record

The figures reconcile Company Financials’ longitudinal series to the annual and interim SEC filings. The 2026 filing reports first-half revenue of $2.657 million, R&D of $45.488 million, G&A of $32.213 million, total operating expense of $77.701 million, and operating loss of $75.044 million. Using the filing avoids an approximately $3 million classification discrepancy in one standardized quarterly series. [S4][S5][S22]

Earnings were structurally at a research-spending low rather than at a conventional cyclical peak or trough: there was no commercial gross-profit cycle, and losses expanded as pivotal development accelerated, so the relevant cycle was cash burn, clinical evidence, and financing availability. A future approval could have created sharp operating leverage, but the company never reached that stage independently.

GAAP, transaction normalization, and earnings quality

The 2025 net loss of $660.0 million was dominated by the approximately $527 million acquired-IPR&D charge. Because that charge represented fair-value accounting for acquired research without alternative future use, it should be removed when comparing routine operating expense across years. Removing it does not produce profitability: core operating expense still exceeded incidental revenue by more than $113 million. [S5]

It would be equally wrong to remove the expense and treat the acquisition as economically free. The transaction committed approximately $519.6 million of value through consideration and the pre-existing interest, before subsequent development. The accounting charge and the economic investment are related but not interchangeable.

Net income and operating cash flow diverged materially because acquired IPR&D, stock compensation, investment marks, warrant remeasurement, digital-asset fair-value changes, depreciation, and working-capital timing were noncash or differently timed; the $660.0 million 2025 net loss versus $102.7 million operating cash outflow is the clearest example. [S4][S5]

In 2023 favorable investment marks helped make net loss much smaller than operating loss. In 2024 and 2025 fair-value movements and acquisition accounting worsened reported net loss relative to ordinary cash burn. ATAI also held equity interests, warrants, available-for-sale securities, and Bitcoin, while pre-funded warrants were recorded as a liability and remeasured through earnings. Reported EPS therefore contained substantial noise unrelated to trial execution.

Stock-based compensation was material but not the main source of dilution. It declined from $63.4 million in 2021 to $14.2 million in 2025, then was $12.9 million in the first half of 2026. Acquisition and financing issuance drove the much larger increase in period-end shares. Because physical capex was generally small, free cash flow approximated operating cash flow; persistent negative free cash flow nevertheless remained economically low quality.

ROIC and research-adjusted returns

The business was not profitable on conventional or research-adjusted terms: accounting ROIC was negative, and no approved-product cash return had been produced from the company’s historical research, acquired programs, and follow-on development. [S4][S5]

Reported R&D from 2021 through the first half of 2026 totaled approximately $338.5 million. Cumulative operating losses over the same periods, before the separately presented IPR&D charge, were approximately $678.3 million. The Beckley transaction committed approximately $519.6 million of value. Those figures establish the scale of capital consumed, but they cannot simply be summed into a precise ROIC denominator: the acquisition consideration already embeds Beckley’s prior research, and some ATAI spending may be represented in the pre-existing interest. Public filings also omit a complete asset-level cost history, attrition schedule, and allocation of corporate costs.

The correct research-adjusted method is therefore two-sided. Normalize the one-time $527 million expense out of recurring operating performance. Retain actual purchase consideration, subsequent development, relevant milestones, and commercialization capital in the economic investment base. Capitalize historical successful R&D using explicit attrition, useful-life, and amortization assumptions, while impairing failed programs. The available record is sufficient to reject a claim of positive realized ROIC but insufficient to report a precise percentage without false accuracy.

This revalidates the relevant prior research principle while correcting the draft’s overstatement. The $527 million acquired-IPR&D fair value is not itself a cash-investment floor, and adding it mechanically to all historical R&D risks double counting. Multiple retrieved formulations of the same principle were duplicates rather than independent learnings.

Balance sheet and liquidity

At June 30, 2026, AtaiBeckley reported $168.8 million of cash, $23.0 million of short-term securities, $34.0 million of other current investments, and $5.9 million of digital assets. Total assets were $264.8 million, total liabilities $88.4 million, and stockholders’ equity $176.4 million. The largest unusual liability was a $57.2 million pre-funded-warrant liability. Long-term Hercules debt had been repaid in 2025. [S4]

The classifications matter. Year-end 2025 cash plus short-term securities was approximately $220.7 million, not $256.0 million; the larger number also includes $35.4 million of other current investments. At June 2026, cash plus short-term securities was approximately $191.8 million. Treating every current investment as risk-free cash would overstate liquidity.

The balance sheet looked net-cash rich relative to reported liabilities, but liquidity was not surplus relative to the complete development plan. The merger forecasts’ $1.25 billion of assumed external capital demonstrate that a standalone enterprise-value calculation could not add all cash without deducting future development funding. [S3]

Accounting conservatism and obligations

Accounting was conservative in immediately expensing internal R&D and acquired research without alternative future use, but reported earnings were not simple or stable because fair-value investments, digital assets, warrants, variable-interest entities, and acquisition accounting introduced material volatility. [S4][S5]

Revenue recognition constrained contingent license payments until achievement was probable and reversal risk sufficiently low. That was appropriate. The VIE model could consolidate entities despite different legal ownership, while some subsidiary liabilities were nonrecourse to the parent. Legal nonrecourse does not always eliminate strategic or reputational incentives to continue funding a program.

Material economic obligations extended beyond recognized debt: clinical contracts, leases, licensing milestones, royalties, contingent consideration, VIE funding choices, and the capital required to finish trials were not fully captured by conventional net debt. [S3][S5]

Physical capital intensity was low, but economic capital intensity was very high because clinical trials, CMC, acquired research, monitoring evidence, regulatory work, and commercialization consumed cash years before revenue. [S3][S4]

Peer context

Compared with commercial neuroscience companies, ATAI lacked revenue, gross profit, and operating leverage. Compared with clinical-stage peers, its financial profile was familiar: repeated R&D losses, dependence on capital markets, and valuation dominated by probability-adjusted assets. Compass’s $433.3 million cash balance and pivotal/NDA stage illustrate how much capital remained necessary even after positive Phase 3 evidence. Lilly’s acquisition was therefore not merely a premium valuation event; it was a transfer of a large remaining funding obligation. [S13]

Verdict: Standalone financial quality was weak—no product revenue, no positive return, persistent cash burn, large dilution, and complex fair-value noise—despite a debt-light balance sheet. Acquisition accounting exaggerated the 2025 GAAP loss, but normalization does not change the absence of self-funded economics. [S3][S4][S5]

Capital Allocation

Capital allocation determined ATAI’s outcome because internally generated operating cash never funded development. Management allocated IPO proceeds, follow-on equity, debt, asset-sale proceeds, and partnership capital across a broad portfolio, then narrowed the portfolio and consolidated Beckley.

The company generated no positive free cash flow: operating cash outflows totaled approximately $436.9 million during 2021-2025 and another $56.4 million in the first half of 2026, with cash used primarily for R&D, personnel, corporate overhead, acquisitions, and portfolio support. [S4][S5]

Portfolio allocation and retrenchment

Early capital supported numerous clinical programs and enabling technologies. Diversification can create real-option value when program outcomes are imperfectly correlated, but it also increases corporate overhead and can spread capital across insufficiently differentiated assets. PCN-101’s failure and subsequent prioritization demonstrated that the platform did not remove program-level risk. Management eventually redirected resources toward BPL-003, VLS-01, and EMP-01.

Cost reduction improved runway, but runway is not return. Spending less on weak programs preserves option value; it does not recover sunk research or demonstrate that the original breadth was optimal. The historical evidence supports credit for adaptation after failure, not proof that early allocation compounded per-share value.

Beckley acquisition record

The Beckley acquisition created the lead asset that drove Lilly’s interest, but its return cannot be isolated cleanly: ATAI issued approximately 103.8 million common-share equivalents to sellers, valued total consideration paid at $465.6 million, included a $53.9 million pre-existing interest, recorded $527 million of acquired IPR&D, and sold the whole company rather than BPL-003 alone. [S4][S5]

This corrects the narrower 81.3 million-share figure in the draft. That amount related to shares covered by a registration statement, not total merger consideration. The 10-Q describes 93.6 million direct shares, 8.7 million RSUs, and 1.5 million options, before technical replacement-award adjustments, plus approximately 0.9 million shares issued to a third party under an amendment. [S4]

Directionally, Beckley was the most important major allocation because BPL-003 became the transaction’s strategic center. A precise return still requires the initial Beckley investments, dilution, transaction costs, subsequent development, acquired cash, and the value Lilly assigned to VLS-01, EMP-01, discovery programs, people, and infrastructure. Comparing Lilly’s $2.8 billion aggregate cash consideration directly with the $527 million accounting charge would falsely label the difference acquisition profit.

The merger background offers a useful counterfactual. In December 2025 another party proposed funding half of global BPL Phase 3 development with $125 million upfront and $50 million upon approval; AtaiBeckley considered the proposal inadequate. The board later explored alternatives, and Lilly ultimately offered fixed cash plus CVRs. This establishes competitive interest while also showing why external funding was central. [S3]

Financing, dilution, and noncore investment

Period-end common shares increased from 160.7 million in 2021 to 168.0 million in 2024, then to 363.3 million in 2025 and 369.2 million by June 2026. The 2025 increase came from the Beckley transaction and financing, not organic per-share compounding. The company reported substantial equity-related proceeds and repaid approximately $21.8 million of Hercules debt. [S4][S5]

ATAI did not repurchase shares through a value-accretive program; the net share count more than doubled during 2025 because acquisition and financing issuance dominated capital allocation. [S5]

The company also invested $10 million in Bitcoin during 2025. That amount was small relative to the acquisition and eventual sale, but it was difficult to justify for a cash-burning clinical company with large future financing needs. The position introduced mark-to-market volatility without advancing trials, protecting intellectual property, or increasing runway predictably. [S4][S5]

The company paid no dividend and had no sustainable dividend capacity because it lacked recurring earnings and free cash flow; preserving research capital was the rational policy. [S5]

Insider issuance and compensation

Material equity awards were issued to employees and directors, although acquisition and financing shares dominated dilution; 2025 option grants to the three named executive officers totaled approximately 6.65 million shares. [S19]

CEO Srinivas Rao’s 2025 compensation was $4.42 million, including $629,200 of salary, $449,878 of incentive compensation, $3.32 million of grant-date option value, and other compensation. The compensation committee assessed corporate, clinical, and financing goals at 130% of target. Options generally vested over four years, while performance awards included clinical and asset-value objectives. [S19]

Executive compensation combined salary, annual cash incentives, and large option grants tied partly to clinical, financing, and asset-value goals; the structure encouraged milestone achievement and transaction value but could reward financing and change-of-control outcomes before commercial ROIC existed. [S3][S19]

The transaction produced substantial insider benefits. Rao’s shares represented approximately $1.46 million of fixed cash consideration, while his options had an estimated cash-out value of approximately $41.9 million and maximum option-related CVR value of approximately $26.7 million. Founder Christian Angermayer’s directly held shares represented approximately $376.5 million of cash and up to $139.4 million of CVR payments. Those interests aligned insiders with closing and some milestone achievement, but could also favor transaction certainty over retaining open-ended standalone upside. [S3]

Insider trading evidence

Management motivations are best inferred cautiously: substantial transaction exposure favored monetization, while the verified June 2026 insider transaction was a 50,000-share option exercise and same-day sale at $5 under a Rule 10b5-1 plan—not an open-market purchase signaling conviction. [S20]

That transaction should not be characterized as informed selling without more evidence because the plan was prearranged and involved an option exercise. Conversely, it cannot support a bullish insider-purchase thesis. The reviewed evidence was insufficient to make a categorical claim that every officer or director avoided purchases across the entire period.

Sale process and CVR negotiation

Shareholders approved the merger with 237,762,253 votes for, 5,033,755 against, and 555,549 abstaining. Approximately 243.4 million of 370.9 million record-date shares were represented, or 65.6%. Support among votes cast was overwhelming, although roughly one-third of record shares were not represented. [S2]

The board obtained fixed cash described as a 40% premium to the prior 30-day VWAP and negotiated three milestone opportunities. It did not obtain every requested protection. The final CVR permitted an offset equal to 50% of specified necessary third-party intellectual-property payments allocated across outstanding CVRs, and a proposed anti-frustration provision was not retained. [S3][S6]

Lilly’s incentives remain broadly aligned because a successful product should be worth more than the CVR payment. Yet alignment is imperfect: former shareholders receive no revenue participation, while Lilly bears every remaining development and commercialization dollar. Rational program termination after weak evidence can maximize Lilly value and reduce CVR value simultaneously.

Verdict: Capital allocation ultimately produced a credible lead asset and strategic exit, but only after substantial cash burn, portfolio attrition, dilution, and a questionable digital-asset investment. The sale was a defensible transfer of financing and execution risk; the record does not demonstrate consistent per-share compounding or positive operating returns. [S3][S4][S5]

Changes and Headwinds — Last Two Years

The business changed fundamentally during the two years before sale. It moved from a capital-constrained Dutch platform with multiple early programs to a Delaware company centered on Beckley’s lead asset, and then to a wholly owned Lilly subsidiary.

Strategy and corporate structure

During 2024, ATAI narrowed spending and sought partners for less-central programs. In November 2025 it completed the Beckley transaction after BPL-003 met agreed development criteria. The combination transformed the program mix and doubled the share count. On December 30, 2025, the registrant became AtaiBeckley Inc., a Delaware corporation. The retrieved company record naming ATAI Life Sciences B.V. was therefore stale even before Lilly completed the acquisition. [S4][S5][S24]

Recent results were driven by both internal execution and external conditions: BPL-003 trial design, enrollment, dose selection, and the Beckley consolidation were management actions, while FDA policy, peer readouts, financing markets, and Lilly’s strategic appetite determined the timing and value of monetization. [S3][S6][S7][S10]

The distinction matters. The acquisition cannot be attributed entirely to a favorable sector, because randomized BPL-003 evidence was company-specific. Nor can it be attributed entirely to management skill, because positive peer results, Spravato growth, and improving strategic interest helped validate the category.

Clinical and regulatory changes

BPL-003 produced positive Phase 2b evidence, received Breakthrough Therapy designation, and advanced into pivotal planning. VLS-01 completed Phase 2 dosing, and EMP-01 supplied exploratory patient evidence. FDA finalized psychedelic-development guidance in July 2026, clarifying expectations around functional unblinding, repeat dosing, long-term safety, psychotherapy, monitoring, abuse potential, and scheduling. [S7][S8][S9][S10]

The business environment changed materially: the sector moved from financing scarcity and program retrenchment toward positive late-stage peer data, clearer FDA guidance, growing treatment infrastructure, and strategic acquisition by a major pharmaceutical company. [S1][S10][S12][S13][S15]

The changes were not uniformly favorable. Better evidence increased strategic value, but more competitors reduced scarcity. Clearer guidance lowered regulatory ambiguity, but required more controlled follow-up, staffing, safety data, and masking analysis. Pivotal readiness improved asset quality while increasing near-term spending.

Management and facilities

Srinivas Rao succeeded Florian Brand as chief executive, and Michael Faerm became CFO effective March 9, 2026. The Beckley combination added U.K. operations and staff as the company increased spending on BPL-003, VLS-01, and EMP-01. The Lilly acquisition then eliminated the need to build an independent public-company and commercial infrastructure. [S4][S19]

Markets, facilities, and management all changed: the company consolidated Beckley’s U.K. research operations, increased clinical spending, installed a new CFO, and transferred the organization to Lilly rather than building a standalone commercial network. [S1][S4][S19]

Physical offices were not the central capacity constraint. Contract manufacturers, clinical investigators, regulated storage, trial sites, and future treatment-center rooms mattered more. Lilly can internalize or contract these functions at greater scale.

Management commentary and transcript contradiction

Company Financials’ two latest available ATAI earnings-call transcripts were Q3 and Q2 2022, so they are historical evidence rather than current guidance. In Q3 2022 management emphasized eight clinical programs, four enabling technologies, and confidence that PCN-101 could support an at-home, non-dissociative profile. It discussed an approximately five-point placebo-adjusted Phase 2 signal as a desirable outcome. The randomized trial subsequently produced only a 1.6-point difference with p=0.5 and missed its primary endpoint. [S18][S22]

That contradiction is instructive. Mechanistic plausibility, portfolio breadth, and confident management commentary did not predict clinical success. Recent evidence should therefore be weighted toward randomized outcomes, regulator records, and contractual definitions, with management presentations treated as hypotheses.

The 2026 investor presentation’s liquidity runway through early 2029 also requires qualification. It described funding for a defined operating plan and expected readouts, not the entire path through approval and commercialization. The merger forecast explicitly assumed $1.25 billion of additional financing. [S3][S7]

Accounting changes and comparability

No disclosed accounting-policy change altered the core economics during the last two years; the largest comparability breaks came from transaction scope—Beckley consolidation, acquired-IPR&D expensing, pre-funded-warrant liability accounting, and fair-value accounting for digital assets. [S4][S5]

The share-count increase and new programs were economic changes, not presentation artifacts. The $527 million IPR&D expense was a presentation discontinuity that should be normalized for ordinary operating comparison while actual consideration remains in economic-return analysis.

Verdict: The last two years improved the quality and strategic value of the lead pipeline while exposing the remaining financing burden and increasing competitive intensity. The decisive change was not a quarterly result but the transition from an independent platform to a Lilly-owned, BPL-led portfolio. [S1][S3][S7]

Risk Analysis

Post-close analysis must separate risks to the former common stock—which has ceased to exist—from risks to CVR payments.

Factors that could have caused the stock to decline before closing included deal failure, clinical disappointment, financing dilution, adverse FDA or DEA action, safety events, weaker peer data, higher discount rates, and lower implied CVR value; after closing, ordinary-stock price risk is replaced by milestone-payment risk. [S3][S10][S22]

Functional unblinding and efficacy

BPL-003’s perceptible psychoactive effect can reveal treatment assignment. Remote raters are useful, but patients may communicate cues and site staff may behave differently. The Phase 2b comparator was a low active dose, while one pivotal study includes placebo and 4 mg. Robust replication requires both pivotal trials to meet their endpoints with coherent durability and no dependence on a small number of sites or experienced psychedelic users. [S7][S10]

A pivotal miss need not mean the molecule lacks biological activity. It could reflect placebo response, patient selection, dose, trial conduct, or measurement noise. For CVR purposes, however, explanatory nuance does not substitute for timely approval.

Safety and label risk

Most BPL-003 events were described as mild or moderate, but nausea, anxiety, blood-pressure elevation, dissociation, vomiting, and suicidal ideation are commercially relevant. An approved label could require more observation, narrower patient eligibility, or additional physician availability. Any of those conditions would reduce throughput and site contribution. [S7][S10]

VLS-01 has less patient evidence. Its two-dose design makes repeated-exposure safety central from Phase 2 onward. EMP-01’s several-hour altered state affects a separate program but demonstrates that not every ATAI asset shared BPL’s proposed short-session advantage.

Regulatory and scheduling risk

The BPL and VLS approval milestones are conjunctive: FDA approval alone is insufficient without DEA rescheduling before the deadline. Approval normally creates the basis for rescheduling from Schedule I into Schedule II-V, so the events are correlated, not independent. Government processing time nevertheless remains an incremental source of deadline risk. [S3][S10]

A late approval can be economically valuable to Lilly and worthless to the CVR if the scheduling condition misses the sunset. The agreement should therefore be modeled according to contractual timing, not an unconstrained probability of eventual approval.

Contract and enforcement risk

The CVR is unlisted, generally nontransferable, and unsecured after an amount becomes due. Holders cannot vote on development, force a particular budget, or exit when evidence changes. Payments can be reduced by the offset mechanism. The commercially reasonable efforts definition gives Lilly meaningful discretion to account for product economics and its broader portfolio. [S3]

Intentional delay solely to avoid a modest payment would be economically irrational if a product is valuable and could create litigation risk. The more credible downside is ordinary scientific attrition, rational reprioritization, manufacturing delay, regulator timing, or a contractual definition not being satisfied.

Financing risk transferred, not disproved

Standalone forecasts required $1.25 billion of external funding. Had the acquisition failed, equity issuance and structured finance would have diluted holders. Lilly removes ATAI-specific financing risk, but that does not prove the independent business was adequately capitalized. It transfers the obligation to an acquirer and caps former-holder upside. [S3]

Catastrophic and total loss

A catastrophic loss for a former holder means the CVR expires at zero because development fails, a program is abandoned, approval or rescheduling misses a deadline, or another contractual condition is not satisfied; the fixed $6.75 cash leg is separate from that residual risk. [S1][S3]

A total loss is possible only on the contingent claim, not on the fixed merger consideration: failure or expiry of all three milestones produces a 100% loss of CVR value, while ordinary ATAI equity no longer exists. [S1][S3]

A zero-CVR outcome is plausible rather than remote because VLS accounts for $2.00 of maximum value without a reported patient-efficacy result, and BPL must cross clinical, FDA, DEA, and timing gates. It is not the base case because BPL has positive randomized evidence and Lilly has strong economic incentives to develop valuable programs.

Verdict: The acquisition removed listed-equity and dilution risk but concentrated former-holder exposure in an illiquid contract. Scientific replication, repeat-dose safety, deadline-sensitive regulation, and precise milestone definitions now determine loss severity. [S3][S7][S8][S10]

Valuation Discussion

A conventional public-company valuation ceased to be actionable at completion. The correct framework separates fixed cash, the CVR, and the much broader asset value retained by Lilly.

Pre-close market implication

The September 10 close of $7.35 less the $6.75 fixed cash consideration implied approximately $0.60 for the CVR before tax, settlement, and closing-risk adjustments. Relative to the $2.50 nominal maximum, the market applied a 76% discount. This was a pre-close residual calculation, not an observable post-close CVR price. [S3][S22]

The market implication combined milestone probabilities, time value, nontransferability, offset risk, tax uncertainty, settlement mechanics, and a small amount of closing risk. Event-driven positioning and forced selling before an illiquid distribution could also affect the final price.

Moelis estimated $0.85-$0.90 using management timing and probabilities and discount rates of 13.25%-15.75%. Centerview calculated approximately $0.87 at 15%. Those values supported the board’s fairness analysis but were not independent clinical opinions or guaranteed realizations. [S3]

Illustrative CVR scenarios

The following are analyst estimates, not management guidance. Probabilities are judgmental and correlated, and the haircut is a simplified representation of potential offsets rather than a contractual forecast.

The base estimate is close to the adviser work but reaches it through transparent assumptions. The bear case reflects VLS’s lack of efficacy data, BPL replication risk, and contractual deadlines. Even the bull case remains below $2.50 because payments received years later have lower present value.

The scenario table is not a portfolio recommendation because the right is not ordinarily purchasable. It is a framework for former holders to understand which evidence changes expected value. A positive VLS Phase 2 result raises both VLS probabilities; a safety or efficacy failure can reduce both. BPL success has only a $0.50 payoff despite potentially large commercial value.

What Lilly bought

The announced upfront aggregate equity value was approximately $2.8 billion, with potential CVRs totaling approximately $1 billion. Lilly acquired all common-equity interests, cash, investments, employees, patents, BPL-003, VLS-01, EMP-01, discovery programs, and unlimited commercial upside. The CVR holders receive none of that residual value beyond three milestone payments. [S1][S6]

At June 30 the company held approximately $191.8 million of cash and short-term securities, plus other investments and digital assets. An enterprise analysis would subtract acquired financial assets but add liabilities, transaction expense, and future development funding. The proxy forecasts assumed $1.25 billion of additional external capital. The headline $2.8 billion therefore cannot be compared directly with a single program’s accounting charge or treated as a clean asset-sale multiple.

Lilly’s bid is the strongest observable strategic valuation datum because it followed diligence and negotiation. It is not a floor for the CVR: the acquirer received every asset and all commercialization upside, while the CVR is capped and conditional.

Management DCF assumptions

Management’s forecast rose from $13 million of revenue in 2030 to $890 million in 2034, $2.8 billion by 2038, and more than $4 billion in later years. EBIT was projected to turn positive in 2032 and reach multi-billion-dollar levels later. These estimates require approval, durable exclusivity, major penetration, favorable pricing, repeat treatment, site capacity, and commercialization execution. [S3]

The back-end growth rate is especially load-bearing because early years contain no revenue and continued cash losses. Small changes in launch timing, probability, peak share, retreatment interval, or protection can move present value substantially. A conventional terminal-value calculation would be inappropriate without a claim-level exclusivity schedule.

Peer context and embedded expectations

Spravato’s $1.696 billion of 2025 sales demonstrates a large commercial channel but carries incumbent evidence and a different dosing schedule. Compass has a higher near-term approval probability because it reported two positive Phase 3 studies and began a rolling NDA. GH Research is the closest mechanism comparator but had not yet delivered Phase 3 evidence. Definium had positive pivotal MDD data but a longer clinic session. These are asset-level comparisons, not interchangeable enterprise multiples. [S12][S13][S14][S15]

The final price embedded several defensible beliefs:

• fixed cash deserved nearly full value once the vote and closing became highly probable;
• the CVR required a large discount to its nominal maximum;
• BPL-003 possessed strategic scarcity value;
• future funding materially reduced standalone value; and
• a takeover premium did not reverse the loss for IPO holders.

Fragile bullish assumptions include successful translation of short duration into reimbursement and clinic contribution, BPL replication despite unblinding, safe retreatment, strong formulation protection, and timely DEA action. Fragile bearish assumptions include treating every supervised psychedelic as operationally identical, assuming first movers foreclose a multi-product market, or expecting Lilly to underinvest in a clearly valuable product merely to avoid a small CVR.

Own-history context and factor exposure

Historical revenue multiples were meaningless, and historical valuation percentiles became obsolete once a cash-and-CVR transaction was signed and completed. The recorded $19.89 high, $1.04 low, and $7.35 final close describe changing financing and clinical expectations rather than a stable valuation distribution. A prior general learning requiring recomputation after a price gap is conceptually sound but superseded here by a complete change in security form. [S21][S22]

The factor model dated September 8 showed high statistical exposure to Market (+1.30) and SmallSize (+1.29), a large negative Liquidity exposure (-1.29), positive Health Care exposure (+0.43), residual volatility of +0.80, near-zero residual momentum, negative residual Sharpe, and R² of only 18.1%. These are dated statistical diagnostics, not legal industry classifications or causal company facts. Low explanatory power is consistent with clinical and takeover events dominating returns. The exposures ceased to describe a tradable ATAI equity after closing. [S23]

Verdict: The final market price implied a conservative but defensible $0.60 CVR value, compared with an illustrative analyst range of approximately $0.34-$1.40 and management-informed adviser values near $0.87. None represents a current entry opportunity because the right is nontransferable and the common equity has ceased trading. [S1][S3][S22]

Variant Perception

The observable pre-close consensus was that the $6.75 cash leg was highly secure and the CVR had positive but heavily discounted value. The $7.35 close implied $0.60, while adviser analyses using management assumptions produced approximately $0.85-$0.90. The gap represented skepticism about probability, timing, liquidity, offsets, tax, or all of them. [S3][S22]

The most thoughtful investor questions concern whether BPL-003’s effect survives functional unblinding in two pivotal trials, whether VLS-01 Phase 2 justifies a qualifying Phase 3, whether FDA and DEA events fit the deadlines, how large IP offsets can become, and whether two-hour sessions create attractive payer and clinic economics. [S3][S7][S8][S10]

Other decision-useful questions include:

• Why did the board accept bounded CVRs rather than retain a tradable VLS-01 spinout?
• What portion of Lilly’s consideration represented BPL-003 versus cash, VLS-01, EMP-01, discovery assets, and personnel?
• Will pivotal disclosures report treatment-assignment guesses and prior psychedelic exposure by arm?
• Will an approved label preserve approximately two-hour discharge readiness?
• Which third-party rights can trigger the offset, and can holders audit the calculation?
• Can a regulator-caused delay after timely submission still cause milestone expiration?
• How will product reformulation or a change in indication interact with contractual definitions?

The merger background partially answers the spinout question. AtaiBeckley considered retaining VLS-01 through a separate structure, and Lilly rejected it while increasing contingent consideration. The company also sought stronger anti-frustration language that did not survive final negotiation. [S3]

Strongest bull case

The strongest bull case is not generalized enthusiasm for psychedelics. It is that Lilly acquired a scarce, clinically credible, short-duration TRD franchise as the category gained commercial and regulatory validation. BPL-003 has randomized evidence, Breakthrough Therapy designation, regulator-aligned pivotal planning, and potential workflow advantages. VLS-01 needs only qualifying Phase 3 initiation for its first $1.00. Lilly has capital, CMC, regulatory, and commercialization expertise, while successful products should be worth much more to Lilly than the CVR payments. Spravato’s sales and peer pivotal progress validate the channel. [S6][S7][S12][S13]

Strongest bear case

The strongest bear case is that most contingent value rests on an unproven program and a chain of deadline-sensitive events. VLS-01 lacked patient efficacy at closing yet represents $2.00 of the maximum. BPL-003 must replicate despite functional unblinding, demonstrate repeated-dose safety, secure approval, and complete scheduling within five years. Lilly can rationally terminate a weak program under the efforts standard. Time value and offsets reduce successful payments, and holders cannot sell when evidence worsens. [S3][S7][S8][S10]

Load-bearing assumptions

1. BPL efficacy: both pivotal studies produce persuasive Week 4 MADRS separation with coherent response, remission, and durability.
2. Workflow: monitoring and REMS preserve a meaningful total-episode advantage, not merely shorter subjective drug effects.
3. VLS translation: Elumina demonstrates sufficient efficacy, safety, exposure consistency, and durability to justify pivotal investment.
4. Timing: clinical, FDA, and DEA processes complete within contractual deadlines.
5. Contract economics: offsets remain modest and Lilly’s choices preserve qualifying product definitions.

Positioning and factor context

Before closing, the factor model described a high-beta, small-size, illiquid, high-residual-volatility stock with low ordinary-factor explanatory power. That matched the economic reality that trial outcomes, financings, and takeover events dominated returns. It did not establish ATAI’s industry classification or predict CVR outcomes. After completion the diagnostic is stale because there is no continuing tradable common stock. [S23]

Prior knowledge revalidation

No prior dated public ATAI report was available, so this is fresh coverage rather than an update against a published recommendation. The retrieved company name was stale: the Dutch ATAI entity became AtaiBeckley Inc. and then a Lilly subsidiary. [S1][S4]

The acquired-IPR&D learning was confirmed with an important refinement. Normalized operating comparisons should exclude the one-time accounting charge, while economic return analysis retains actual transaction consideration and subsequent development. The draft’s proposed $860 million research-capital floor was not defensible because adding IPR&D fair value to historical R&D can double count embedded research. Unrelated learnings concerning AI adoption, utilities, restaurants, banks, and mortgage REITs had no evidence-supported transfer to ATAI and were omitted.

The own-history cheapness learning became stale because a completed acquisition replaced the security and valuation framework. The broader takeover learning survived: an arm’s-length bid is valuable evidence about strategic asset value, but access to that value depends on the exact security and contractual rights.

Verdict: Before closing, the non-consensus opportunity was to value the CVR explicitly rather than treating $9.25 as guaranteed consideration. After closing there is no tradable arbitrage; the remaining analytical edge is disciplined monitoring of contractual definitions and disconfirming clinical evidence. [S1][S3][S8]

Fact vs. Interpretation

Facts are strongest around transaction terms, voting, historical financials, and trial design. BPL-003’s evidence is intermediate because it is randomized but sponsor-reported and unreplicated in Phase 3. VLS-01 lacks patient-efficacy evidence, and commercial conclusions remain inference because no ATAI product has launched. [S3][S4][S7][S8]

Open Questions

1. What are the complete Elumina efficacy, safety, dropout, masking, and pharmacokinetic results for VLS-01?
2. What development plan will qualify for the VLS-01 Phase 3-initiation milestone, and when will its first patient be dosed?
3. Will BPL-003 pivotal disclosures include treatment-assignment guesses, prior psychedelic exposure, and site-level consistency?
4. Is the controlled pivotal period eight or twelve weeks under the final protocol, resolving the investor-presentation inconsistency?
5. What monitoring duration, staffing, REMS, transport, and driving restrictions will FDA impose if BPL-003 is approved?
6. Which third-party intellectual-property agreements could trigger the CVR offset, and what audit rights do holders have?
7. How will Lilly prioritize BPL-003 and VLS-01 relative to its broader neuroscience portfolio?
8. What issued and pending claims, regulatory exclusivities, and realistic workarounds define BPL-003’s protection?
9. Can FDA and DEA actions reasonably complete before the fifth- and seventh-anniversary sunsets?
10. What periodic information will the rights agent provide before a milestone is achieved or expires?
11. How should individual holders allocate basis and report later payments under applicable tax rules?

The open questions should be updated using regulator records, trial registries, peer-reviewed results, SEC filings, and rights-agent notices rather than management adjectives or social-media interpretations. The absence of VLS efficacy and a claim-level patent schedule are valuation limitations, not blanks that should be filled with optimistic assumptions. [S3][S8][S10]

What Must Be True

Bull tests

• VLS-01 must produce credible randomized Phase 2 efficacy. Confirmation would be clinically meaningful Day 29 MADRS separation, coherent durability, manageable severe events, acceptable retention, and exposure consistency. The premise is falsified by failure of the prespecified endpoint, no durable separation, or a safety or PK problem requiring fundamental redesign. [S8]

• Lilly must start a qualifying VLS Phase 3 trial before September 11, 2030. Confirmation is first dosing of the first patient under a qualifying protocol. Registration, planning, regulator discussion, or site activation alone does not satisfy the contractual test. [S3]

• BPL-003 must replicate in two adequate pivotal studies. Confirmation requires successful Week 4 MADRS endpoints, coherent response and remission, durability, acceptable site consistency, and interpretable masking evidence. A material miss in either pivotal study, placebo response that erases separation, or repeat-dose safety that makes the intended label unattractive would falsify the premise. [S7][S10]

• Regulatory implementation must preserve the product proposition. Confirmation would be an approved label with feasible monitoring, an operationally manageable REMS, and timely DEA rescheduling. Materially longer observation, exclusion of core patients, or scheduling after the fifth anniversary would impair or eliminate the BPL milestone. [S3][S10]

• Offsets must remain modest. Confirmation is rights-agent payment near the stated $1.00, $0.50, and $1.00 amounts. Material necessary-IP payments that reduce awards would falsify the assumption. [S3]

Bear tests

• The commercially addressable category must prove much narrower than clinical prevalence. Bear confirmation would include slow site activation, restrictive coverage, weak paid conversion, limited patient willingness, or poor contribution per room-hour. The bear premise is falsified if supervised products continue expanding paid adoption with attractive reimbursement and site utilization. Spravato’s $1.696 billion of 2025 sales is already meaningful counterevidence. [S11][S12][S16]

• Short-session differentiation must fail to create economic value. Bear confirmation would be a BPL label requiring long monitoring or matched-site evidence showing no capacity or cost advantage. The premise is falsified if sites demonstrate higher daily throughput, lower episode cost, and broader access than long-session alternatives. FDA’s two-monitor expectation means pharmacological duration alone is insufficient. [S7][S10][S15]

• Lilly must rationally deprioritize one or both CVR programs. Confirmation would be enrollment pauses, missed milestones, or termination after weak data. The premise is falsified by timely pivotal initiation, manufacturing scale-up, regulatory submissions, and milestone achievement. The efforts covenant permits rational portfolio considerations but does not eliminate Lilly’s economic incentive to develop valuable products. [S3]

• The pre-close CVR discount must reflect weak science rather than primarily illiquidity. Confirmation would be adverse VLS or BPL evidence pushing expected value toward zero. The premise is falsified if milestones are achieved on time and near their stated amounts, demonstrating that the $0.60 pre-close implication was overly conservative. [S3][S22]

The monitoring hierarchy is prespecified randomized efficacy first; serious safety and masking evidence second; regulator records third; qualifying trial initiation fourth; contractual payment notices fifth; and management adjectives last. Primary documents include the Lilly completion announcement, definitive merger proxy, FDA psychedelic-drug guidance, and latest AtaiBeckley Form 10-Q.

Public source appendix

• S1: Lilly completes acquisition of AtaiBeckley — company release; published 2026-09-11; Completion announcement; successful closing and surviving wholly owned subsidiary
• S2: AtaiBeckley special-meeting Form 8-K — SEC filing; published 2026-09-08; Items 5.07 and 8.01; record shares, represented shares, voting table and expected closing
• S3: AtaiBeckley definitive merger proxy — SEC filing; published 2026-08-10; Transaction Summary; Background; Forecasts; Adviser Opinions; CVR Agreement; Interests of Directors and Officers; Tax Consequences
• S4: AtaiBeckley Form 10-Q for quarter ended June 30, 2026 — SEC filing; published 2026-08-11; Financial statements; cash flow; liquidity; Beckley acquisition consideration; share equivalents; R&D; fair-value measurements
• S5: AtaiBeckley 2025 Form 10-K — SEC filing; published 2026-03-06; Business; Risk Factors; MD&A; financial statements; acquired IPR&D; liquidity; accounting policies; five-year financial data
• S6: Lilly agreement to acquire AtaiBeckley — company release; published 2026-07-16; Transaction terms, premium, aggregate consideration and strategic rationale
• S7: AtaiBeckley 2026 investor-day presentation — SEC-filed company presentation; published 2026-03-06; BPL-003 Phase 2b efficacy and safety; ReConnection designs; discharge readiness; development timing and liquidity
• S8: AtaiBeckley doses last patient in VLS-01 Phase 2b study — company release; published 2026-07-06; Elumina randomized design, enrollment, primary and secondary endpoints, dosing completion and expected topline timing
• S9: AtaiBeckley reports EMP-01 Phase 2a topline results — company release; published 2026-02-26; Enrollment, safety objective, LSAS result, effect size, one-tailed p-value, CGI-I and adverse events
• S10: FDA final guidance: Psychedelic Drugs—Considerations for Clinical Investigations — regulatory guidance; published 2026-07-14; Functional unblinding, dose response, durability, repeat dosing, psychotherapy, monitoring, abuse potential and scheduling
• S11: FDA-approved Spravato prescribing information — regulatory label; publication date unavailable; TRD indication; dosing frequency; REMS; direct supervision; two-hour monitoring and driving restriction
• S12: Johnson & Johnson 2025 Form 10-K — SEC filing; published 2026-02-11; Sales to Customers table; Spravato U.S., international and worldwide sales for 2023-2025
• S13: Compass Pathways second-quarter 2026 results and business highlights — peer company release; published 2026-08-05; Two Phase 3 results, rolling NDA, possible launch timing, cash, debt, runway and operating expense
• S14: GH Research announces FDA lift of GH001 clinical hold — peer company release; published 2026-01-05; Clinical-hold resolution, Phase 3 plan and sponsor-reported Phase 2b efficacy, duration and discharge metrics
• S15: Definium reports positive Phase 3 Emerge results for DT120 — SEC-filed peer release; published 2026-06-22; Enrollment, Week 6 and Week 12 MADRS results, safety, monitoring and discharge timing
• S16: NIMH major-depression prevalence statistics — government statistics; publication date unavailable; 2021 U.S. adult prevalence, severe impairment, treatment and methodology note
• S17: Relative effectiveness of treatments in treatment-resistant depression — peer-reviewed systematic review; published 2024-12-30; Abstract and results; TRD definition; 69 trials; 10,285 participants; treatment comparisons and limitations
• S18: ATAI announces Phase 2a PCN-101 results — company release; published 2023-01-06; Primary-endpoint miss, MADRS results, p-value and trial design
• S19: AtaiBeckley 2026 definitive annual-meeting proxy — SEC filing; published 2026-04-22; Executive compensation, incentive metrics, option grants, vesting and employment arrangements
• S20: Gerd Kochendoerfer Form 4 — SEC insider filing; published 2026-06-29; June 26 option exercise and 50,000-share sale under a Rule 10b5-1 plan
• S21: ATAI announces pricing of upsized initial public offering — company release; published 2021-06-17; IPO price, initial share count and gross proceeds
• S22: Company Financials — configured financial-data service; publication date unavailable; NASDAQ:ATAI ticker resolution; profile; annual and quarterly statements; historical prices; Q2 and Q3 2022 earnings-call transcripts; values reconciled to SEC filings
• S23: The factor model—ATAI snapshot — internal quantitative diagnostic; published 2026-09-08; Exposures, residual signals and diagnostics dated September 8, 2026
• S24: ATAI 2024 Form 10-K — SEC filing; published 2025-03-17; Business, pipeline, intellectual property, risk factors, 2024 financial statements and liquidity
• S25: ATAI 2023 Form 10-K — SEC filing; published 2024-03-28; Business, program prioritization, 2023 financial statements, accumulated deficit and liquidity